在患有慢性脏病的狗中,阿姆洛迪平改善了对称二甲基氨酸的作用
Shohei Morita1, Youhei Mochizuki2, Takahiro Kondo1
1Koganei Animal Medical Emergency Center, Tokyo University of Agriculture and Technology, Tokyo, Japan.
Frontiers in veterinary science
|May 15, 2025
概括
在患有慢性病 (CKD) 的狗中,安洛迪平治疗降低了对称二甲基氨基 (SDMA) 水平,表明功能有所改善. 这种效应在高血压和非高血压的狗中都被观察到,这表明amlodipine.
科学领域:
- 兽医医学 兽医医学 兽医医学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
背景情况:
- 狗的慢性病 (CKD) 通常与高血压有关.
- 氨基是用于治疗犬类高血压的常见药物.
- 阿姆洛迪平对狗功能的影响,特别是SDMA水平,以前是未知的.
研究的目的:
- 为了评估安洛迪平对血清对称二甲基氨 (SDMA) 水平的影响,在被诊断为CKD的狗中.
- 为了比较高血压与非高血压犬中SDMA水平的变化,用阿姆洛迪平治疗的CKD.
- 评估amlodipine在治疗有或没有高血压的犬类CKD中的安全性和有效性.
主要方法:
- 追溯性研究设计.
- 纳入标准:具有持续升高SDMA (≥14μg/dL) 的狗被诊断患有CKD并接受了阿姆洛迪平治疗.
- 收集的数据:品种,性别,年龄,血液化学,血压,心率,阿姆洛迪平注射前后心声图. 狗被分为高血压 (HT) 和非高血压 (非HT) 组.
主要成果:
- 在高血压和非高血压的CKD狗中,阿姆洛迪平剂后,SDMA水平的平均值显著下降.
- 在所有接受阿姆洛迪平的CKD狗中,心脏输出 (CO) 增加.
- 在阿姆洛迪平治疗后,高血压和非高血压组的血压下降.
结论:
- 阿姆洛迪平的使用改善了CKD犬的SDMA水平,不管它们的高血压状态如何.
- 心脏输出量增加可能有助于改善淋巴膜过率和减少SDMA.
- 阿姆洛迪平似乎是一种安全有效的治疗方法,可以改善CKD的狗的功能,包括正常压力的人.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
334
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
334
01:22Heart Failure Drugs: Diuretics
298
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
298
01:25Antihypertensive Drugs: Direct Renin Inhibitors
458
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
458
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
413
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
413
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
417
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
417
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
548
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
548